Study at a glance
What did vitamin D studies measure about stress and health?
A winter trial tested vitamin D3 against placebo in 86 men at a secure treatment institution. It measured body responses to a laboratory stress task. A separate population survey examined allostatic load, a count of selected abnormal health measurements. Neither measurement was a direct score of the everyday ability to cope with stress.
Did vitamin D improve the measured responses to stress?
Vitamin D blood levels rose with supplementation and fell with placebo. However, the main comparisons did not show that treatment significantly changed heart-rate patterns during stress and recovery. A recovery pattern within the vitamin D group did not by itself prove a difference from placebo. Serotonin and cortisol measurements also did not establish a treatment effect or explain improved stress recovery. Blood serotonin was not a measure of brain serotonin.
Were lower vitamin D levels linked with poorer health measurements?
Lower vitamin D levels were linked to higher odds of having several abnormal measurements, including blood pressure, blood fats and other health markers. The researchers used four versions of the score in overlapping groups, not four independent trials. These scores did not directly measure psychological stress, stress hormones or recovery after a challenge. The paper also reported some numbers describing the links inconsistently.
Do these studies show that vitamin D helps people cope with stress?
The trial involved a specialised male population, and fewer participants had usable measurements than were assigned treatment. The survey measured existing differences at one point, so illness, lifestyle or other factors could explain the association. It could not show that supplements reduced the score. Together, the studies do not establish vitamin D as a treatment for stress or a way to improve the everyday ability to cope with stress.
Read the full article below ↓A winter supplementation trial changed vitamin D status but did not establish a significant treatment effect on its main stress-response interactions. A separate population study linked lower vitamin D status with a higher biomarker-risk count. Together, the papers illustrate why laboratory recovery, cumulative biological risk and everyday psychological resilience must remain distinct. For the shorter account, see Vitamin D, Laboratory Stress Responses and Allostatic Load: Study Summary.
This VD3FL analysis uses both complete principal papers and their material tables and figures, Frei’s supplementary table and Hansen’s current registry record. Hansen’s audio supplement was decoded, not audibly assessed or acoustically calibrated.
Two different meanings of stress-related evidence
Hansen and colleagues studied physiological responses during a laboratory challenge in a randomised trial. Frei and colleagues analysed a cross-sectional survey using allostatic load, a count of selected abnormal biomarkers. The studies therefore address different questions, even though both are discussed in relation to Vitamin D and Stress Physiology.
A trial can test the effect of assigned treatment within its population and measurement conditions. A survey can identify associations across people, but generally cannot establish whether changing an exposure changes an outcome. Putting the two papers together does not remove the limitations of either design.
Neither study directly measured a person’s ability to recover psychologically from every kind of real-world adversity. The useful synthesis concerns what each measurement can support and where the authors’ broader language exceeds the specific results.
The winter trial and its participants
Hansen’s trial randomised 86 male forensic inpatients at one secure US treatment institution, 43 per arm. Participants were aged 31-81, with a mean age around 48. Personality and substance-use disorders and histories of adversity were common. This is a specialised setting, not a representative sample of healthy adults or all people with stress-related symptoms.
The intervention was 40 micrograms, equivalent to 1,600 IU, of oral vitamin D3 daily, compared with an olive-oil placebo. Supplementation ran from January into May 2018. The follow-up testing window began in April, so exposure at testing was not exactly the same duration for every participant. This regimen describes research, not a recommendation for readers.
The paper describes blinding and coded supplement allocation. The current registry contains differing structured and narrative masking descriptions, and its original version history was not compared here. It is therefore more accurate to describe the published procedures than to claim perfect agreement between every registration field and the article.
Seventy-eight participants were retained, but usable outcome samples were smaller. The flow diagram reports 68 with heart-rate variability data, 69 with serotonin data and 71 with cortisol data. These are outcome-specific available-case analyses. Assigning all 86 randomised participants to every result would overstate the available evidence.
The status table also prints a post-treatment vitamin D-arm denominator that disagrees with the flow diagram and analysis degrees of freedom. That discrepancy is retained as a reporting limitation rather than silently repaired. The planned sample-size calculation concerned separation in vitamin D status, not demonstrated power for every stress-response interaction.
What the laboratory challenge measured
Participants completed cognitive tasks accompanied by aversive noise, with ECG measurements during baseline, challenge and recovery. High-frequency heart-rate variability, abbreviated HF-HRV, reflects a particular aspect of beat-to-beat variation under the recording conditions. It is not a direct numerical scale of psychological resilience.
The paper describes sessions lasting roughly 60-90 minutes and participant-selected noise levels judged uncomfortable but not painful. The supplied audio file confirms a stimulus file exists; decoding it does not independently establish the sound level delivered in the room or reconstruct the entire session.
Morning blood samples measured serum 25-hydroxyvitamin D and peripheral serotonin. Serum serotonin is not a direct measure of brain serotonin, and it was not sampled repeatedly around the stress task. This distinction matters when relating the trial to Vitamin D and Brain.
Seven saliva samples covered evening, awakening-related and stress-related times. The collection schedule offers information about cortisol across the day, but staff-dependent morning collection limited exact awakening timing. The challenge did not produce a statistically significant pooled pre-to-post stress cortisol rise. A weakly elicited response constrains conclusions about its modification.
Status changed, but the treatment interactions were not significant
Average vitamin D status increased from 63 to 76 nmol/L in the supplemented group and fell from 59 to 47 nmol/L in the placebo group. The group-by-time interaction was significant, P<.001. This establishes a treatment-related status difference under the trial conditions, not an optimal blood target.
For HF-HRV, however, the group-by-time-by-condition interaction was not significant, P=.125. That interaction addresses whether the response pattern across baseline, challenge and recovery changed differently between the treatment groups. The corresponding interaction for heart rate was also not significant, P=.636.
The authors reported a significant recovery contrast within the vitamin D arm after treatment and a nonsignificant contrast within placebo. Those findings can be described as within-arm patterns. They do not, by themselves, establish that the arms differed significantly in their changes.
This is a fundamental interpretation issue: a significant result in one group and a nonsignificant result in another is not equivalent to a significant difference between the groups. The appropriate comparison has to be tested directly. The nonsignificant interactions also do not prove exactly zero effect, particularly with small samples and uncertain precision.
One post-treatment baseline-to-stress contrast in the vitamin D group had an unadjusted P=.036, which did not meet the authors’ adjusted criterion of .013. A broad description of completely restored or normal responses would omit this qualification. The plotted shapes are informative, but they cannot override the statistical comparisons.
Serotonin and cortisol do not establish a mechanism
The serotonin group-by-time interaction was not significant, P=.87. Both groups showed a seasonal decline. The trial therefore did not establish that vitamin D preserved serotonin or that serotonin mediated improved stress recovery.
Cortisol showed a strong pooled time-of-day pattern, but no significant treatment effects were reported. This is not evidence that vitamin D normalised HPA-axis function; the broader physiology is described in Vitamin D and the HPA Axis. A diurnal hormone pattern is also different from proving an improved response to a stress challenge.
The study links conceptually to Vitamin D and Neuroendocrine Integration, while leaving the proposed coordination of endocrine and autonomic responses unresolved. HRV can be influenced by respiration, medication, autonomic state and recording conditions. Repeated-task familiarity and missing outcome data add further uncertainty.
Some serum vitamin D-serotonin correlations were reported, but correlations are not demonstrated mediators. The age-adjusted association between vitamin D and post-treatment HRV recovery was itself nonsignificant, P=.067. The paper does not establish a complete chain from supplement to hormone change to clinically meaningful resilience.
What allostatic load meant in the population study
Frei’s study used NHANES III data collected in 1988-1994 from non-institutionalised US adults. It related serum 25-hydroxyvitamin D to counts of abnormal biomarkers. Survey weights addressed the sampling design, nonresponse and population calibration; weighting does not turn the analysis into an experiment.
The first index used nine components: systolic and diastolic blood pressure, pulse, total and HDL cholesterol, glycated haemoglobin, waist-to-hip ratio, albumin and C-reactive protein. The second added body mass index, triglycerides, creatinine and two herpes-simplex seropositivity measures, making fourteen components.
Each component set was scored using either predetermined cut points or sample-based quartiles. This produced four versions of the index. All used a score of at least three to classify high allostatic load, despite their different numbers of components. Their prevalences are therefore not interchangeable measurements of a single stress dose.
These indices did not include cortisol, catecholamines, a subjective stress history or a measured stress-recovery response. They combine cardiovascular, metabolic and other risk markers. Vitamin D and Homeostatic Balance supplies the wider physiological context, but the index is not a direct test of how successfully an individual maintains every aspect of homeostasis.
The nine-component sample included 14,213 people; the fourteen-component sample included 4,620. Complete adjusted and stratified analyses were smaller. These are overlapping survey samples with different data availability, not independent replications of equal size.
The association and an important reporting discrepancy
Lower vitamin D status was associated with higher odds of prevalent high allostatic load in the principal adjusted comparisons. Table 3 gives lowest-versus-highest vitamin D quartile odds ratios of 1.53, 1.59, 1.88 and 1.61 for the four index versions, respectively.
The corresponding 95% confidence intervals were 1.32-1.77, 1.27-1.98, 1.46-2.43 and 1.24-2.08. These values are specifically from Table 3. The abstract and prose give a different range, so combining their range with the table’s intervals would conceal a source inconsistency.
An odds ratio concerns odds, not an equivalent percentage change in probability. High allostatic load was common, making that distinction material. Nor were these ratios estimates of future disease incidence or the effect of giving vitamin D.
Adjustment covered demographic, socioeconomic and lifestyle factors and self-rated health. Medication was discussed in additional analyses, but should not be automatically added to the displayed full-model definition. The supplementary linear models express differences in score units; a difference of 0.20 points is not a 20% reduction in stress.
The index includes inflammation-related measurements, connecting it with Vitamin D and Inflammatory Signalling, but an association with a composite cannot identify which biological pathway caused the result. Correlated components and equal weighting also influence the meaning of the total score.
Why the survey cannot establish stress treatment
Low status and higher biomarker burden may share causes, including illness, activity, diet, body composition and socioeconomic circumstances. Reverse causation is possible. Vitamin D and Body Fat is particularly relevant because body mass index was itself included in the larger index, rather than being wholly separate from its outcome.
Season and geography were intertwined in survey sampling: northern sites were sampled in summer and southern sites in winter. A single blood measurement does not reconstruct long-term vitamin D exposure. The large losses from missing biomarkers, especially for the fourteen-component index, may also affect who remains represented.
Not every subgroup or intermediate-quartile comparison was significant. The excellent-self-rated-health stratum did not show a significant lowest-versus-highest association. Larger estimates in one age group do not establish an age interaction unless that difference is formally tested.
Self-reported supplement use was not a randomised exposure and did not show a clear association with the nine-component index. The four index versions and multiple statistical models are sensitivity analyses of overlapping data, not four independent trials of supplementation.
Putting the findings together
The trial provides experimental evidence that supplementation changed status, but its relevant autonomic treatment interactions were not significant. The survey provides evidence that status and a composite biomarker burden were associated, with unresolved direction of causation. Neither establishes a general stress-resilience treatment.
This distinction between nutritional status, molecular response and meaningful outcomes is developed further in Vitamin D Response. The two papers should encourage clearer measurement and appropriately powered studies, rather than conversion of suggestive physiological patterns into promises of psychological benefit.
Hansen’s research received institutional support, and Pharma Nord supplied study products; the authors declared no conflicts or funder role in analysis and reporting. Frei’s authors reported no specific funding or competing interests. These disclosures are part of the evidence context, not proof that either interpretation is automatically correct.
Conclusion
Vitamin D status changed convincingly in the winter trial, while the main treatment comparisons for stress-response patterns remained nonsignificant. Lower status was associated with a higher allostatic-load count in the survey, but that count was not a direct measure of psychological stress. The evidence does not establish supplementation as a way to improve everyday resilience or reverse cumulative stress.
Scientific sources
Hansen AL, Ambroziak G, Thornton D, and colleagues. Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial. Nutrients. 2020;12(11):3258. DOI 10.3390/nu12113258; PMID 33114392.
Frei R, Haile SR, Mutsch M, Rohrmann S. Relationship of Serum Vitamin D Concentrations and Allostatic Load as a Measure of Cumulative Biological Risk among the US Population: A Cross-Sectional Study. PLOS ONE. 2015;10:e0139217. DOI 10.1371/journal.pone.0139217; PMID 26451600.
ClinicalTrials.gov. Key Nutrients and Mental Health. Trial registration. NCT03336125; current record, not a comparison of every historical version.
Related reading
Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial
This study investigated the effects of vitamin D supplements during winter on biological markers of stress resilience such as psychophysiological activity, serotonin, and cortisol in a placebo-controlled, randomized clinical trial.
Original paper ↗Read more →Vitamin D, Laboratory Stress Responses and Allostatic Load: Study Summary
Summary of a winter supplementation trial and a population study, separating stress-response measurements from claims about everyday psychological resilience.
Read more →Vitamin D, Cortisol and Glucocorticoid Responses: Full Study
Compare vitamin D trials on cortisol and fatigue with glucocorticoid cell studies.
Read more →From Glucocorticoid Responses in Cells to HPA Feedback
Understand why vitamin D effects in immune-cell cultures do not establish restored HPA feedback, and what the human cortisol studies actually measured.
Read more →Salivary cortisol in long COVID: a marker of broader stress system and circadian rhythm dysregulation
This prospective, single-center, case: control study was conducted at a Long COVID clinic in Rome between February 2023 and March 2024 and included 96 participants evaluated at least 28 days after confirmed SARS-CoV-2 infection.
Original paper ↗Read more →Vitamin D3 Improves Hypothalamic-Pituitary-Adrenal Axis Function, Immunological Responses, and Gut Dysbiosis in Sleep Desynchrony
Chronic sleep desynchrony proliferates in modern society, characterized by extended wakefulness and disrupted circadian rhythms over a long period, and is associated with various physiological and immune dysfunctions.
Original paper ↗Read more →Vitamin D, Cortisol and Glucocorticoid Responses: Study Summary
A short guide to vitamin D trials on cortisol and fatigue, plus glucocorticoid cell findings and the limits of claims about HPA feedback.
Read more →Vitamin D and Stress Physiology
Explore how vitamin D participates in stress physiology through neuroendocrine signalling, HPA-axis regulation, immune coordination, energy reprioritisation, and recovery timing.
Read more →A Pharmacogenetic Study of VDR fok1 and TYMS Polymorphisms and Their Association With Glucocorticoid-Induced Osteonecrosis in Egyptian Children With Acute Lymphoblastic Leukemia
This study aimed to investigate the relationship between vitamin D receptor fok1 (VDR fok1) and thymidylate synthase (TYMS) gene polymorphisms with the glucocorticoid (GC) induced osteonecrosis (ON) in Egyptian pediatric ALL patients.
Original paper ↗Read more →Adrenalectomy Reduces the Risk of Vertebral Fractures in Patients With Mild Autonomous Cortisol Secretion
The aim was to investigate impact of recovery from MACS on bone health remains unclear.
Original paper ↗Read more →Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials
The purpose of this paper is to use the method of network meta-analysis (NMA) to compare the efficacy of anti-osteoporosis drugs directly and indirectly, and to explore the advantages of various anti-osteoporosis drugs based on the current evidence.
Original paper ↗Read more →Glucocorticoids dexamethasone and prednisolone suppress fibroblast growth factor 23 (FGF23)
Fibroblast growth factor 23 (FGF23) is a hormone mainly secreted by bone cells.
Original paper ↗Read more →Hair cortisol in polycystic ovary syndrome
The aim of the study was to evaluate adrenal axis hyperactivation measuring hair cortisol levels, and its influence on the relationship among metabolic parameters, inflammation markers and androgens in adult women with PCOS.
Original paper ↗Read more →Mineral Metabolism Assays, Central DXA, and Fracture Risk Probabilities in Menopausal Patients with Non-Functional Adrenal Tumors with/Without Mild Autonomous Cortisol Secretion: Does the Presence of Unilateral Versus Bilateral Tumors Matter?
Hence, we aimed to analyze (blood) mineral metabolism assays (MMAs), including bone turnover markers (BTMs), central Dual-Energy X-ray Absorptiometry (DXA), and 10-year fracture risk estimation (FRAX/FRAXplus) in menopausal patients with UTs vs.
Original paper ↗Read more →No requirement of perioperative glucocorticoid replacement in patients with endogenous Cushing’s syndrome: a pilot study
Surgical therapy represents the first-line treatment for endogenous Cushing’s syndrome (CS).
Original paper ↗Read more →Prognostic Value of CRP/25 OH Vitamin D Ratio for Glucocorticoid Efficacy in Acute Severe Ulcerative Colitis Patients
Our study aimed to create a new ASUC algorithm to predict corticosteroid response in the early course of the disease.
Original paper ↗Read more →Serotonin, melatonin and their precursors and metabolites and vitamin D3 derivatives in honey
We are commenting recent discoveries on the presence of L-DOPA, dopamine, 5-hydroxytryptophan, tryptamine, serotonin, N-acetylserotonin, melatonin, 2-hydroxymelatonin, AFMK and AMK in honey.
Original paper ↗Read more →SOST/Sclerostin impairs the osteogenesis and angiogesis in glucocorticoid-associated osteonecrosis of femoral head
Here this study is aimed to identify whether sclerostin played an essential role in the occurrence and development of GA-ONFH.
Original paper ↗Read more →The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: A cohort study
We compared definitions of glucocorticoid exposure and their associated risk of fracture.
Original paper ↗Read more →Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis
We investigated the potential of vitamin D (VD) to enhance GC efficacy and the mechanisms underlying this VD/GC interaction.
Original paper ↗Read more →Vitamin D and the HPA Axis
Explore how vitamin D interacts with the HPA axis and the body’s central stress-response system, including hormonal signalling, immune: endocrine coordination, circadian rhythm, and metabolic adaptation.
Read more →Original sources
Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial
Published in Nutrients (2020).
Publication details
Hansen AL, Ambroziak G, Thornton D, and colleagues. Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial. Nutrients. 2020;12(11):3258. DOI 10.3390/nu12113258; PMID 33114392.
Key Nutrients and Mental Health
ClinicalTrials.gov. Key Nutrients and Mental Health.
Publication details
ClinicalTrials.gov. Key Nutrients and Mental Health. Trial registration. NCT03336125; current record, not a comparison of every historical version.